An open mind on adaptive designs

Good Clinical Practice Journal

Volumn 15, Issue 12, 2008, Pages 19-22

  Day, Simon ^a   Småstuen, Milada Cvancarova ^b,c  

^a ROCHE PRODUCTS LTD   (United Kingdom)

^b CANCER REGISTRY OF NORWAY   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Adaptive design; ASTIN trial; Continual reassessment method (CRM); Flexible design; Statistical methodology; Type I error

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; CANCER RESEARCH; CLINICAL RESEARCH; CLINICAL STUDY; CLINICAL TRIAL; DOSE RESPONSE; DRUG RESEARCH; GOOD CLINICAL PRACTICE; HUMAN; LOW DRUG DOSE; MALIGNANT NEOPLASTIC DISEASE; METHODOLOGY; OUTCOME ASSESSMENT; QUALITATIVE RESEARCH; QUALITATIVE VALIDITY; RESEARCH PRIORITY; RISK BENEFIT ANALYSIS; SAMPLING ERROR; UNSPECIFIED SIDE EFFECT;

EID: 62849089952     PISSN: 13500961     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. JB van Helmont. 'Oriatrike or Physik, Refined' (translated by J. Chandler). Lodowick Loyd, London, 1662.
2. P Gallo, C. Chuang-Stein V Dragalin. et al. 'Adaptive Designs in Clinical Drug Development -An Executive Summary of the PhRMA Working Group'. Journal of Biopharmaceutical Statistics, 16(3). pp275-283, 2006.
3. Committee for Medicinal Products for Human Use (CHMP). Reflertion paper on methodological issues in confirmatory clinical trials planned with an adaptive design. (CHMP/EWP/2459/02). European Medicines Agency, London, 2007 (.http://www.emea,europa.eu/pdfs/human/ewp/245902enadopted.pdf).
4. S-C Chow, M Chang. 'Adaptive design methods in clinical trials - a review' Orphanet Journal of Rare Diseases, 3(11), 2008.
5. J O'Quigley, M Pepe, L. Fisher. 'Continual reassessment method: a practical design for phase I clinical trials in cancer'. Biometrics, 46(1), pp33-48, 1990.
6. E Garrett-Mayer. 'The continual reassessment method for dose-finding, a tutorial', Clinical Trials, 3(1), pp57-71, 2006.
7. EA Gehan. 'The determination of the number of patients nequired in a preliminary and a follow-up trial of a new chemotherapeutic agent', Journal of Chronic, Diseases, 13(4). pp346-353, 1961.
8. M Krams, KR Lees, W Hacke, et al. 'Acute stroke therapy by inhibition of neutrophils (ASTIN). An adaptive dose-response study of UK. 279,276 in acute ischemic stroke', Stroke, 34, pp2543-2548, 2003.
9. L Di Scala, L Pylvanainen. B Molloy, et al. 'A novel Bayesian dose-escalation phase Ib design investigating safety of combination of RAD001 with chemotherapy plus trastuzumab in patients with HER2-overexpressing metastatic breast cancer with prior resistance to trastuzumab' (Abstract). Journal of Clinical Oncology, 16, 15S, p1130, 2008.
10. The CAPRICORN Investigators. 'Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction. The CAPRICORN randomised trial', Lancet, 357, pp1385-1390, 2001.